ReviewHuman vaccines & immunotherapeutics2013
Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy.
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Targeting Cancer: Microenvironment and Immunotherapy Innovations.International journal of molecular sciences · 2024Review
- Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines.Frontiers in pharmacology · 2021Review
- Article
- [Immunological tumor therapy].Der Internist · 2015Review
- Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Cancer research · 2015Review
- Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.Cancer research · 2014Article
- A biotin-streptavidin-biotin bridge dramatically enhances cell fusion.Oncology letters · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusions of antigen presenting cells and tumor cells have been investigated in animal models and phase I/II clinical trials as candidate cancer vaccines. In animal studies there have been numerous reports of induction of protective immunity against a wide range of tumor types. Results of clinical trials have been less dramatic, but tumor-specific immune responses have been reported in many patients, with clinical responses to the vaccination in a subset. In this commentary article, I review the current status of antigen presenting cell/tumor cell fusion vaccines for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.